Core Viewpoint - The company, Jian Shi Technology-B (09877), has received registration approval from the New Zealand Medicines and Medical Devices Safety Authority for its transcatheter aortic valve replacement system Ken-Valve and transcatheter tricuspid valve replacement system LuX-ValvePlus, which will accelerate the global commercialization of its product portfolio [1][5]. Group 1 - Jian Shi Technology-B's stock price initially rose over 8% in the morning but later adjusted to a slight increase of 0.24%, trading at HKD 8.50 with a transaction volume of HKD 3.4321 million [1][5]. - The company is actively promoting the commercialization of Ken-Valve and LuX-ValvePlus in New Zealand following their recent registration approval [1][5]. - The announcement highlights that the products have gained broad market recognition due to their design advantages, ongoing clinical trials, and continuous therapy promotion efforts [1][5].